Literature DB >> 33205354

Extent of resection and survival outcomes in World Health Organization grade II meningiomas.

Pranay Soni1,2, Mark A Davison1, Jianning Shao3, Arbaz Momin3, Diana Lopez3, Lilyana Angelov1,2,3, Gene H Barnett1,2,3, Joung H Lee4, Alireza M Mohammadi1,2,3, Varun R Kshettry1,2,3, Pablo F Recinos5,6,7.   

Abstract

PURPOSE: WHO grade II meningiomas behave aggressively, with recurrence rates as high as 60%. Although complete resection in low-grade meningiomas is associated with a relatively low recurrence rate, the impact of complete resection for WHO grade II meningiomas is less clear. We studied the association of extent of resection with overall and progression-free survivals in patients with WHO grade II meningiomas.
METHODS: A retrospective database review was performed to identify all patients who underwent surgical resection for intracranial WHO grade II meningiomas at our institution between 1995 and 2019. Kaplan-Meier analysis was used to compare overall and progression-free survivals between patients who underwent gross total resection (GTR) and those who underwent subtotal resection (STR). Multivariable Cox proportional-hazards analysis was used to identify independent predictors of tumor recurrence and mortality.
RESULTS: Of 214 patients who underwent surgical resection for WHO grade II meningiomas (median follow-up 53.4 months), 158 had GTR and 56 had STR. In Kaplan-Meier analysis, patients who underwent GTR had significantly longer progression-free (p = 0.002) and overall (p = 0.006) survivals than those who underwent STR. In multivariable Cox proportional-hazards analysis, GTR independently predicted prolonged progression-free (HR 0.57, p = 0.038) and overall (HR 0.44, p = 0.017) survivals when controlling for age, tumor location, and adjuvant radiation.
CONCLUSIONS: Extent of resection independently predicts progression-free and overall survivals in patients with WHO grade II meningiomas. In an era of increasing support for adjuvant treatment modalities in the management of meningiomas, our data support maximal safe resection as the primary goal in treatment of these patients.

Entities:  

Keywords:  Atypical meningioma; Extent of resection; Overall survival; Progression-free survival; Simpson grade; WHO grade II meningioma

Year:  2020        PMID: 33205354     DOI: 10.1007/s11060-020-03632-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  28 in total

1.  Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States.

Authors:  Varun R Kshettry; Quinn T Ostrom; Carol Kruchko; Ossama Al-Mefty; Gene H Barnett; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2015-05-24       Impact factor: 12.300

2.  Meningioma recurrence rates following treatment: a systematic analysis.

Authors:  Victor Lam Shin Cheung; Albert Kim; Arjun Sahgal; Sunit Das
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

3.  The accuracy of meningioma grading: a 10-year retrospective audit.

Authors:  J Willis; C Smith; J W Ironside; S Erridge; I R Whittle; D Everington
Journal:  Neuropathol Appl Neurobiol       Date:  2005-04       Impact factor: 8.090

4.  Radiotherapy for atypical meningiomas.

Authors:  Richard Mair; Kevin Morris; Ian Scott; Thomas A Carroll
Journal:  J Neurosurg       Date:  2011-06-24       Impact factor: 5.115

5.  Atypical Meningiomas: Recurrence, Reoperation, and Radiotherapy.

Authors:  Daniel R Klinger; Bruno C Flores; Jeremy J Lewis; Kimmo Hatanpaa; Kevin Choe; Bruce Mickey; Samuel Barnett
Journal:  World Neurosurg       Date:  2015-04-25       Impact factor: 2.104

Review 6.  Intracranial meningiomas of atypical (WHO grade II) histology.

Authors:  Leland Rogers; Mark Gilbert; Michael A Vogelbaum
Journal:  J Neurooncol       Date:  2010-08-26       Impact factor: 4.130

7.  The role of radiotherapy following gross-total resection of atypical meningiomas.

Authors:  Ricardo J Komotar; J Bryan Iorgulescu; Daniel M S Raper; Eric C Holland; Kathryn Beal; Mark H Bilsky; Cameron W Brennan; Viviane Tabar; Jonathan H Sherman; Yoshiya Yamada; Philip H Gutin
Journal:  J Neurosurg       Date:  2012-08-24       Impact factor: 5.115

8.  The impact of adjuvant stereotactic radiosurgery on atypical meningioma recurrence following aggressive microsurgical resection.

Authors:  Douglas A Hardesty; Andrew B Wolf; David G Brachman; Heyoung L McBride; Emad Youssef; Peter Nakaji; Randall W Porter; Kris A Smith; Robert F Spetzler; Nader Sanai
Journal:  J Neurosurg       Date:  2013-02-08       Impact factor: 5.115

9.  Outcome of resection of WHO Grade II meningioma and correlation of pathological and radiological predictive factors for recurrence.

Authors:  Anil Nanda; Shyamal C Bir; Subhas Konar; Tanmoy Maiti; Piyush Kalakoti; Jamie A Jacobsohn; Bharat Guthikonda
Journal:  J Clin Neurosci       Date:  2016-07-15       Impact factor: 1.961

10.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.

Authors:  Quinn T Ostrom; Gino Cioffi; Haley Gittleman; Nirav Patil; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2019-11-01       Impact factor: 12.300

View more
  5 in total

1.  Why we need new classification models in meningioma management.

Authors:  Marco V Corniola
Journal:  Acta Neurochir (Wien)       Date:  2022-01-24       Impact factor: 2.216

2.  Establishment and Validation of an Integrated Model to Predict Postoperative Recurrence in Patients With Atypical Meningioma.

Authors:  Xiao-Yong Chen; Jin-Yuan Chen; Yin-Xing Huang; Jia-Heng Xu; Wei-Wei Sun; Yue- Chen; Chen-Yu Ding; Shuo-Bin Wang; Xi-Yue Wu; De-Zhi Kang; Hong-Hai You; Yuan-Xiang Lin
Journal:  Front Oncol       Date:  2021-10-07       Impact factor: 6.244

3.  Extent of resection and survival outcomes in the World Health Organization Grade II meningiomas.

Authors:  Gustavo R Isolan; Rafael Roesler
Journal:  Surg Neurol Int       Date:  2022-04-08

4.  DNA Methylation Associates With Clinical Courses of Atypical Meningiomas: A Matched Case-Control Study.

Authors:  Matthias Millesi; Alice Senta Ryba; Johannes A Hainfellner; Thomas Roetzer; Anna Sophie Berghoff; Matthias Preusser; Gerwin Heller; Erwin Tomasich; Felix Sahm; Karl Roessler; Stefan Wolfsberger
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

Review 5.  Molecular determinants of outcomes in meningiomas.

Authors:  John Lynes; Gabriel Flores-Milan; Sebastian Rubino; John Arrington; Robert Macaulay; James K C Liu; Andre Beer-Furlan; Nam D Tran; Michael A Vogelbaum; Arnold B Etame
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.